Dr. John Roberts
Add to your Care-Team
Dr. John Roberts
Dr. John Roberts
I specialize in
I have been in practice
My answers and insights have
Helped 70 people
Received 1 doctor agrees
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
Oregon Health & Science University School of Medicine
Risk prediction for complex diseases: application to Parkinson disease.
Genet. Med., Dec (2012)
Common variation in the LRRK2 gene is a risk factor for Parkinson's disease.
Mov. Disord., Oct (2012)
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee.
PLoS Genet., Aug;7(8):e1002237 (2011)
Contralateral prophylactic mastectomy.
Ann Plast Surg., Sep;67(3):215-9 (2011)
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.
Arch. Neurol., Nov;67(11):1350-6 (2010)
A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.
Neurology., Sep;75(13):1189-94 (2010)
Monitoring and reducing exposure of infants to pollutants in house dust.
Rev Environ Contam Toxicol., 201:1-39 (2009)
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Mov. Disord., Nov;23(15):2177-85 (2008)
Genetic association between alpha-synuclein and idiopathic Parkinson's disease.
Am. J. Med. Genet. B Neuropsychiatr. Genet., Oct;147B(7):1222-30 (2008)
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.
Arch. Neurol., Mar;65(3):379-82 (2008)
Exploring gene-environment interactions in Parkinson's disease.
Hum. Genet., Apr;123(3):257-65 (2008)
Elucidating mechanisms of recurrent laryngeal nerve injury during thyroidectomy and parathyroidectomy.
J. Am. Coll. Surg., Jan;206(1):123-30 (2008)
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.
Eur. J. Neurol., Feb;15(2):134-9 (2008)
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
Mov. Disord., Jan;23(1):88-95 (2008)
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease.
Ann. Neurol., Aug;62(2):137-44 (2007)
DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease.
Ann. Neurol., Jul;62(1):99-101 (2007)
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease.
Genet. Test., 10(3):221-7 (2006)
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.
Am. J. Hum. Genet., Oct;79(4):752-8 (2006)
Collective bacterial dynamics revealed using a three-dimensional population-scale defocused particle tracking technique.
Appl. Environ. Microbiol., Jul;72(7):4987-94 (2006)
Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease.
Neurology., Aug;67(4):697-9 (2006)
A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.
Neurology., Sep;65(5):741-4 (2005)
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Ann. Neurol., Jul;36(1):27-31 (1994)
D-cycloserine treatment of Alzheimer disease.
Alzheimer Dis Assoc Disord., 8(3):198-205 (1994)
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Neurology., Dec;43(12):2685-8 (1993)
End-of-dose dystonia in Parkinson's disease.
Neurology., Oct;43(10):2130-1 (1993)
Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus.
Am. J. Hum. Genet., Oct;49(4):851-4 (1991)
Dr. John Roberts M